Holistic multiprofile model of cardiometabolic risk: from preclinical phenotyping to structural and functional damage to the heart and blood vessels

Cover Page
  • Authors: Khabibulina M.M.1, Salikova S.P.2, Seliverstov P.V.2, Fedorets V.N.3, Tsurtsumiya D.B.4, Shamilov M.D.1, Alieva P.M.5, Chupanova A.T.6, Davydova D.R.7
  • Affiliations:
    1. Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation
    2. Federal State Budgetary Military Educational Institution of Higher Education “S.M. Kirov Military Medical Academy” of the Ministry of Defence of the Russian Federation
    3. Federal State Budgetary Educational Institution of Higher Education “Saint-Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation
    4. Federal State Budgetary Educational Institution of Higher Education “I.I. Mechnikov North-Western State Medical University” of the Ministry of Health of the Russian Federation
    5. Federal State Budgetary Educational Institution of Higher Education “Dagestan State Medical University” of the Ministry of Health of the Russian Federation
    6. Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation
    7. Federal State Budgetary Educational Institution of Higher Education “Yaroslavl State Medical University” of the Ministry of Health of the Russian Federation
  • Issue: Vol 24, No 4 (2026)
  • Pages: 23-31
  • Section: Original research
  • URL: https://journals.eco-vector.com/1728-2918/article/view/717229
  • DOI: https://doi.org/10.29296/24999490-2026-04-04
  • EDN: https://elibrary.ru/zqvfal
  • ID: 717229

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Non-communicable diseases develop long before clinical manifestation, and their subclinical signs may be missed by one-dimensional risk assessment. A holistic multiprofile approach combining somatic, psychoemotional and behavioural determinants may improve cardiometabolic risk stratification.

Objective: to validate the applicability of a holistic multiprofile model of cardiometabolic risk assessment at the preclinical and clinical stages of its development.

Material and methods. Block 1 included 177 women with oestrogen deficiency and grade I–II arterial hypertension: 85 with normal body weight and 92 with metabolically healthy abdominal obesity; the control group included 90 apparently healthy women. Echocardiography, brachial artery endothelium-dependent vasodilation testing, common carotid artery duplex scanning, Holter monitoring, ambulatory blood pressure monitoring, laboratory assessment and psychosomatic profiling were performed. Block 2 included remote multiprofile screening of 3155 students and cluster analysis of a prospective follow-up group of 157 participants.

Results. In women with metabolically healthy abdominal obesity, despite comparable blood pressure levels, more pronounced endothelial dysfunction, left ventricular remodelling, diastolic abnormalities and an unfavourable psychosomatic profile were revealed. In the preclinical block, 56.4% of young adults had medium or high risk in at least one non-communicable disease profile, and 75.7% had multiprofile risk. Cluster analysis identified 4 phenotypes with distinct psychosomatic patterns.

Conclusion. The holistic multiprofile approach detects clinically significant differences hidden by one-dimensional risk assessment and may serve as a basis for personalized cardiometabolic stratification.

About the authors

Marina M. Khabibulina

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: m.xabibulina@mail.ru
ORCID iD: 0000-0002-3240-1357
SPIN-code: 3456-9089

Associate Professor at the Department of Outpatient Therapy; Candidate of Medical Sciences

Russian Federation, Repina St., 3, Yekaterinburg, 620028

Svetlana P. Salikova

Federal State Budgetary Military Educational Institution of Higher Education “S.M. Kirov Military Medical Academy” of the Ministry of Defence of the Russian Federation

Email: salikova.1966@bk.ru
ORCID iD: 0000-0003-4839-9578

Professor of the 2nd Department of Advanced Therapy for Physicians; Doctor of Medical Sciences

Russian Federation, Akademika Lebedeva St., 6, Saint-Petersburg, 194044

Pavel V. Seliverstov

Federal State Budgetary Military Educational Institution of Higher Education “S.M. Kirov Military Medical Academy” of the Ministry of Defence of the Russian Federation

Email: seliverstov-pv@yandex.ru
ORCID iD: 0000-0001-5623-4226
SPIN-code: 6166-7005

Associate Professor, 2nd Department (Advanced Therapy Training); Candidate of Medical Sciences, Associate Professor

Russian Federation, Akademika Lebedeva St., 6, Saint-Petersburg, 194044

Viktor N. Fedorets

Federal State Budgetary Educational Institution of Higher Education “Saint-Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation

Email: victor.fedorets@gmail.com

Professor of the Department of Hospital Therapy with a course in Endocrinology; Doctor of Medical Sciences

Russian Federation, Litovskaya St., 2, Saint-Petersburg, 194100

Darejan B. Tsurtsumiya

Federal State Budgetary Educational Institution of Higher Education “I.I. Mechnikov North-Western State Medical University” of the Ministry of Health of the Russian Federation

Email: D.Tcurtcumiya@szgmu.ru
ORCID iD: 0000-0001-7806-9364

Associate Professor of the Department of Internal Diseases, Nephrology, General and Clinical Pharmacology with a course in Pharmacy; Candidate of Medical Sciences

Russian Federation, Piskarevsky Ave., 47, Saint-Petersburg, 195067

Mark D. Shamilov

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation

Email: mark_shamilov@mail.ru
ORCID iD: 0009-0009-0197-8354

sixth-year student, Faculty of General Medicine

Russian Federation, Repina St., 3, Yekaterinburg, 620028

Patimat M. Alieva

Federal State Budgetary Educational Institution of Higher Education “Dagestan State Medical University” of the Ministry of Health of the Russian Federation

Email: alieva.p04@icloud.com
ORCID iD: 0009-0003-9008-5457

sixth-year student

Russian Federation, 1 Lenin Square, Makhachkala, Republic of Dagestan, 367005

Alina T. Chupanova

Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation

Email: acupanova5@gmail.com
ORCID iD: 0009-0002-5505-5028

fifth-year student

Russian Federation, 1 Ostrovityanova St., Bldg. 6, Moscow, 117513

Diana R. Davydova

Federal State Budgetary Educational Institution of Higher Education “Yaroslavl State Medical University” of the Ministry of Health of the Russian Federation

Email: blek.kassandra@mail.ru
ORCID iD: 0009-0006-8088-1275

sixth-year student

Russian Federation, 5 Revolyutsionnaya St., Yaroslavl, 150000

References

  1. GBD 2019 Non-Communicable Diseases Collaborators. The global burden of non-communicable diseases attributable to dietary risks in 2019. Lancet. 2022; 400 (10349): 357–69. doi: 10.1016/S0140-6736(22)01167-9.
  2. Государственный доклад о состоянии здоровья населения Российской Федерации в 2023 году. М.: ФГБУ «ЦНIIОИЗ» Минздрава России, 2024. [State Report on the Health of the Population of the Russian Federation in 2023. Moscow: FGBU TsNIIOIZ, 2024 (In Russ.)]
  3. Ndumele C.E., Rangaswami J., Chow S.L. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the AHA. Circulation. 2023; 148 (20): 1606–35. doi: 10.1161/CIR.0000000000001184.
  4. Mancia G., Kreutz R., Brunstrom M. et al. 2023 ESH Guidelines for the management of arterial hypertension. J. Hypertens. 2023; 41 (12): 1874–2071. doi: 10.1097/HJH.0000000000003480.
  5. McEvoy J.W., McCarthy C.P., Bruno R.M. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 2024; 45 (38): 3912–4018. doi: 10.1093/eurheartj/ehae178.
  6. Kivimaki M., Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018; 15 (4): 215–29. doi: 10.1038/nrcardio.2017.189.
  7. World Health Organization. Noncommunicable Diseases Progress Monitor 2023. Geneva: WHO; 2023.
  8. Engel G.L. The need for a new medical model: a challenge for biomedicine. Science. 1977; 196 (4286): 129–36. doi: 10.1126/science.847460.
  9. Eriksson M., Lindstrom B. Antonovsky’s sense of coherence scale and the relation with health: a systematic review. J. Epidemiol Community Health. 2006; 60 (5): 376–81. doi: 10.1136/jech.2005.041616.
  10. Хабибулина М.М. , Шамилов М.Д., Цурцумия Д.Б. и др. Молекулярные механизмы кардиометаболического фенотипа при АГ и ожирении у женщин. Молекулярная медицина. 2026; 24 (3): 44–52. doi: 10.29296/24999490-2026-03-06. [Khabibulina M.M., Shamilov M.D., Tsurtumiya D.B. et al. Molecular Mechanisms of the Cardio-Metabolic Phenotype in Women with Hypertension and Obesity. Molekulyarnaya meditsina. 2026; 24 (3): 44–52 (In Russ.)]
  11. Хабибулина М.М. Структурно-геометрические изменения ЛЖ и ЭЗВД у женщин с АГ в пременопаузе. Кардиоваскулярная терапия и профилактика. 2011; 10 (2): 24–8. doi: 10.15829/1728-8800-2011-2-24-28. [Khabibulina M.M. Structural and geometric changes in the LV and EF in women with AH in premenopause. Kardiovaskulyarnaya terapiya i profilaktika. 2011; 10 (2): 24–8 (In Russ.)]
  12. Хабибулина М.М. Показатели сосудистого русла у женщин с АГ в пременопаузе. Терапевтический архив. 2011;83(12):11–15. [Khabibulina M.M. Vascular parameters in premenopausal women with hypertension. Terapevticheskiy arkhiv. 2011; 83 (12): 11–5 (In Russ.)]
  13. Хабибулина М.М. Влияние гипоэстрогенемии на качество жизни женщин с АГ в пременопаузе. Кардиология. 2013; 53 (11): 45–8. [Khabibulina M.M. The impact of hypoestrogenemia on the quality of life of women with AH in premenopause. Kardiologiya. 2013; 53 (11): 45–8 (In Russ.)]
  14. Хабибулина М.М. Психовегетативный статус и ББИМ в пременопаузе при МЗО. Врач. 2019; 30 (4): 79–83. doi: 10.29296/25877305-2019-04-15. [Khabibulina M.M. Psychovegetative status and BBI in premenopause with MZO. Vrach. 2019; 30 (4): 79–83 (In Russ.)]
  15. Хабибулина М.М., Елистратов Д.Г. Психокоррекционная терапия пациенток с МЗАО. Врач. 2024; 35 (4): 36–41. doi: 10.29296/25877305-2024-04-07. [Khabibulina M.M., Elistratov D.G. Psychocorrectional therapy for patients with MZAO. Vrach. 2024; 35 (4): 36–41 (In Russ.)]
  16. Хабибулина М.М., Шамилов М.Д. Антигипертензивная и кардиометаболическая терапия при АГ. Врач. 2025; 36 (4): 49–54. doi: 10.29296/25877305-2025-04-09. [Khabibulina M.M., Shamilov M.D. Antihypertensive and cardiometabolic therapy for AH. Vrach. 2025; 36 (4): 49–54 (In Russ.)]
  17. Хабибулина М.М., Шамилов М.Д. Влияние метаболической терапии на сосудистое русло при дислипидемии в пременопаузе. Врач. 2023; 34 (5): 83–8. doi: 10.29296/25877305-2023-05-15. [Khabibulina M.M., Shamilov M.D. The effect of metabolic therapy on the vascular bed in premenopausal dyslipidemia. Vrach. 2023; 34 (5): 83–8 (In Russ.)]
  18. Хабибулина М.М., Шамилов М.Д. Терапия АГ в зависимости от генотипа гена эстрогеновых рецепторов. Врач. 2023; 34 (8): 68–74. [Khabibulina M.M., Shamilov M.D. Treatment of hypertension depending on the genotype of the estrogen receptor gene. Vrach. 2023; 34 (8): 68–74 (In Russ.)]
  19. Хабибулина М.М., Елистратов Д.Г., Шамилов М.Д. Современная терапия нарушений ритма у пациентов с АГ и ожирением. Врач. 2024; 35 (5): 58–62. doi: 10.29296/25877305-2024-05-11. [Khabibulina M.M. et al. Modern therapy for rhythm disorders in patients with AH and obesity. Vrach. 2024; 35 (5): 58–62. (In Russ.)]
  20. Хабибулина М.М. Выявление ББИМ у женщин с АГ и кардиалгией в пременопаузе. Российский кардиологический журнал. 2011; 6: 14–8. [Khabibulina M.M. Detection of BBI in women with AH and cardalgia in premenopause. Rossiyskiy kardiologicheskiy zhurnal. 2011; 6: 14–8 (In Russ.)]
  21. Хабибулина М.М. Кардиоваскулярный риск при эстрогенодефиците в доклимактерических периодах. Екатеринбург, 2014; 193. [Khabibulina M.M. Cardiovascular risk in estrogen deficiency. Yekaterinburg, 2014; 193 (In Russ.)]
  22. Хабибулина М.М., Шамилов М.Д. Структурно-функциональное ремоделирование сердца и сосудов при АГ и МЗАО у женщин с эстрогенодефицитом. Молекулярная медицина. 2026. [Khabibulina M.M., Shamilov M.D. Structural and functional remodeling of the heart and blood vessels in women with estrogen deficiency and AH and MZAO. Molekulyarnaya meditsina. 2026 (In press; In Russ.)]
  23. Schulze M.B., Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat Rev Endocrinol. 2024; 20 (11): 633–46. doi: 10.1038/s41574-024-01008-5.
  24. Mongraw-Chaffin M., Foster M.C., Anderson C.A.M. et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 2018; 71 (17): 1857–65. doi: 10.1016/j.jacc.2018.02.055.
  25. Della Rocca D.G., Pepine C.J. What causes heart failure with preserved ejection fraction? Circ Heart Fail. 2022; 15 (3): e009129. doi: 10.1161/CIRCHEARTFAILURE.121.009129.
  26. Nagueh S.F., Smiseth O.A., Appleton C.P. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc Echocardiogr. 2016; 29 (4): 277–314. doi: 10.1016/j.echo.2016.01.011.
  27. Ras R.T., Streppel M.T., Draijer R., Zock P.L. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int. J. Cardiol. 2013; 168 (1): 344–51. doi: 10.1016/j.ijcard.2012.09.047.
  28. Davezac M., Buscato M., Zahreddine R. et al. Estrogen receptor and vascular aging. Front Aging. 2021; 2: 727380. doi: 10.3389/fragi.2021.727380.
  29. Mehta J.M., Manson J.E. The menopausal transition period and cardiovascular risk. Nat Rev Cardiol. 2024; 21 (3): 203–11. doi: 10.1038/s41569-023-00926-7.
  30. Koenen M., Hill M.A., Cohen P., Sowers J.R. Obesity, adipose tissue and vascular dysfunction. Circ Res. 2021; 128 (7): 951–68. doi: 10.1161/CIRCRESAHA.121.318093.
  31. Griendling K.K., Camargo L.L., Rios F.J. et al. Oxidative stress and hypertension. Circ Res. 2021; 128 (7): 993–1020. doi: 10.1161/CIRCRESAHA.121.318063.
  32. Kajikawa M., Higashi Y. Obesity and endothelial function. Biomedicines. 2022; 10 (7): 1745. doi: 10.3390/biomedicines10071745.
  33. Abukhodair A.W., Alghurabi B., Abukhodair A.K. A comprehensive review of ADMA in cardiovascular diseases. Curr Cardiol Rev. 2021; 17 (5): e230421187144. doi: 10.2174/1573403X16999200824142239.
  34. Shu H., Cheng J., Li N. et al. Obesity and atrial fibrillation: arrhythmogenic mechanisms and clinical significance. Cardiovasc Diabetol. 2023; 22: 192. doi: 10.1186/s12933-023-01913-5.
  35. Селиверстов П.В. Медицинская методология дистанционного анкетного скрининга ХНИЗ у лиц молодого возраста. Диссертация д.м.н. Санкт-Петербург: ВМА им. С.М. Кирова, 2026. [Seliverstov P.V. Medical methodology of remote questionnaire screening of CNID in young people. Doctoral dissertation. Saint-Petersburg: S.M. Kirov MMA, 2026 (In Russ.)]
  36. Селиверстов П.В. Телемедицинский скрининг ХНИЗ: система «Телемед 3». Молекулярная медицина. 2025. [Seliverstov P.V. Telemedicine screening of HCNIZ: the Telemed3 system. Molekulyarnaya meditsina. 2025 (In Russ.)]
  37. Селиверстов П.В. Патент РФ №2693160. Дистанционный анкетный скрининг ХНИЗ. 2019. Реестр российского ПО №5799. [Seliverstov P.V. Remote questionnaire screening of the NHS. 2019. Registry of Russian software No. 5799. 2019 (In Russ.)]
  38. Селиверстов П.В., Крюков Е.В., Гриневич В.Б. Практическая реализация технологий искусственного интеллекта при проведении профилактического медицинского осмотра. Медицинский совет. 2025; 13: 266–72. doi: 10.21518/ms2025-322. [Seliverstov P.V., Kryukov E.V., Grinevich V.B. Practical implementation of artificial intelligence technologies during preventive medical examination. Medicinskij sovet. 2025; 13: 266–72 (In Russ.)]
  39. Селиверстов П.В., Шаповалов В.В., Кравчук Ю.А. и др. Искусственный интеллект в ранней диагностике: интеграция донозологического скрининга и персонализированной профилактики ХНИЗ. Молекулярная медицина. 2025; 5: 70–8. doi: 10.29296/24999490-2025-05-08. [Seliverstov P.V., SHapovalov V.V., Kravchuk Yu.A. et al. Artificial intelligence in early diagnosis: integration of prenosological screening and personalized prevention of chronic kidney disease. Molekulyarnaya medicina. 2025; 5: 70–8 (In Russ.)]
  40. Topol E.J. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25 (1): 44–56. doi: 10.1038/s41591-018-0300-7.
  41. Jiang F., Jiang Y., Zhi H. et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017; 2 (4): 230–43. doi: 10.1136/svn-2017-000101.
  42. Снегирева Л.В., Шайдеров М.Е. Цифровые технологии в профилактической медицине. Профилактическая медицина. 2024; 27 (4): 12–8. [Snegireva L.V., Skhayderov M.E. Digital technologies in preventive medicine. Profilakticheskaya meditsina. 2024; 27 (4): 12–8 (In Russ.)]
  43. Селиверстов П.В., Гриневич В.Б., Шаповалов В.В., Крюков Е.В. Повышение эффективности скрининга ХНИЗ с использованием технологий на основе искусственного интеллекта. Лечащий Врач. 2024; 4 (27): 97–104. doi: 10.51793/OS.2024.27.4.014. [Seliverstov P.V., Grinevich V.B., SHapovalov V.V., Kryukov E.V. Improving the effectiveness of screening for NCDs using artificial intelligence-based technologies. Lechashchij Vrach. 2024; 4 (27): 97–104 (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Russkiy Vrach Publishing House